HAEM5:In situ follicular B-cell neoplasm - Revision history

Bailey.Glen at 17:17, 3 July 2025

2025-07-03T17:17:22Z

← Older revision		Revision as of 12:17, 3 July 2025
Line 34:		Line 34:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:36, 25 May 2025

2025-05-25T21:36:48Z

← Older revision		Revision as of 16:36, 25 May 2025
Line 141:		Line 141:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 244:		Line 244:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 277:		Line 277:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''
Line 323:		Line 323:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene; Genetic Alteration!!~~'''~~Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)~~'''~~!!~~'''~~Prevalence (COSMIC / TCGA / Other)~~'''~~!!~~'''~~Concomitant Mutations~~'''~~!!~~'''~~Mutually Exclusive Mutations~~'''~~		!Gene; Genetic Alteration!!Presumed Mechanism (Tumor Suppressor Gene [TSG] / Oncogene / Other)!!Prevalence (COSMIC / TCGA / Other)!!Concomitant Mutations!!Mutually Exclusive Mutations
	!~~'''~~Diagnostic Significance (Yes, No or Unknown)~~'''~~		!Diagnostic Significance (Yes, No or Unknown)
	!Prognostic Significance (Yes, No or Unknown)		!Prognostic Significance (Yes, No or Unknown)
	!Therapeutic Significance (Yes, No or Unknown)		!Therapeutic Significance (Yes, No or Unknown)
	!Notes		!Notes
	\|-		\|-
	\|~~'''~~''CREBBP~~'''~~'' inactivating missense variants (various); mutation hotspots in exons 24-28 and exon 30.		\|''CREBBP'' inactivating missense variants (various); mutation hotspots in exons 24-28 and exon 30.
	\|TSG		\|TSG
	\|32.6%<ref name=":0">{{Cite journal\|last=Pasqualucci\|first=Laura\|last2=Dominguez-Sola\|first2=David\|last3=Chiarenza\|first3=Annalisa\|last4=Fabbri\|first4=Giulia\|last5=Grunn\|first5=Adina\|last6=Trifonov\|first6=Vladimir\|last7=Kasper\|first7=Lawryn H.\|last8=Lerach\|first8=Stephanie\|last9=Tang\|first9=Hongyan\|date=2011-03\|title=Inactivating mutations of acetyltransferase genes in B-cell lymphoma\|url=https://www.nature.com/articles/nature09730\|journal=Nature\|language=en\|volume=471\|issue=7337\|pages=189–195\|doi=10.1038/nature09730\|issn=1476-4687}}</ref>		\|32.6%<ref name=":0">{{Cite journal\|last=Pasqualucci\|first=Laura\|last2=Dominguez-Sola\|first2=David\|last3=Chiarenza\|first3=Annalisa\|last4=Fabbri\|first4=Giulia\|last5=Grunn\|first5=Adina\|last6=Trifonov\|first6=Vladimir\|last7=Kasper\|first7=Lawryn H.\|last8=Lerach\|first8=Stephanie\|last9=Tang\|first9=Hongyan\|date=2011-03\|title=Inactivating mutations of acetyltransferase genes in B-cell lymphoma\|url=https://www.nature.com/articles/nature09730\|journal=Nature\|language=en\|volume=471\|issue=7337\|pages=189–195\|doi=10.1038/nature09730\|issn=1476-4687}}</ref>
Line 340:		Line 340:
	<br />		<br />
	\|-		\|-
	\|~~'''~~''EZH2~~'''~~''		\|''EZH2''
	p.Y646, p.A682G, p.A692V		p.Y646, p.A682G, p.A692V
	Gain of function variants. Y646 may have multiple amino acid replacements		Gain of function variants. Y646 may have multiple amino acid replacements

Bailey.Glen at 20:13, 25 May 2025

2025-05-25T20:13:08Z

← Older revision		Revision as of 15:13, 25 May 2025
Line 49:		Line 49:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|In situ follicular neoplasia
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|Follicular lymphoma in situ
	\|}		\|}

Bailey.Glen at 17:37, 24 March 2025

2025-03-24T17:37:56Z

← Older revision		Revision as of 12:37, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:In situ follicular B-cell neoplasm}}		{{DISPLAYTITLE:In situ follicular B-cell neoplasm}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 13:		Line 12:

	Rachel D. Burnside, PhD, MBA, FACMGG		Rachel D. Burnside, PhD, MBA, FACMGG

	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Jennelleh at 13:01, 7 March 2025

2025-03-07T13:01:44Z

@@ Line 36: / Line 36: @@
 |Subtype(s)
 |In situ follicular B-cell neoplasm
 |}
@@ Line 204: / Line 138: @@
 |No
 |No
-|The translocation results in the juxtaposition of the BCL2 major or minor breakpoint cluster with the VDJ region of IGH during erroneous VDJ recombination<ref name=":1" /><ref>{{Cite journal|last=Sotomayor|first=Edgar A.|last2=Shah|first2=Inangati M.|last3=Sanger|first3=Warren G.|last4=Mark|first4=Hon Fong L.|date=2007-10-01|title=In situ follicular lymphoma with a 14;18 translocation diagnosed by a multimodal approach|url=https://www.sciencedirect.com/science/article/pii/S001448000700038X|journal=Experimental and Molecular Pathology|volume=83|issue=2|pages=254–258|doi=10.1016/j.yexmp.2007.03.001|issn=0014-4800}}</ref>
+|The translocation results in the juxtaposition of the BCL2 major or minor breakpoint cluster with the VDJ region of IGH during erroneous VDJ recombination<ref name=":1">{{Cite journal|last=Jegalian|first=Armin G.|last2=Eberle|first2=Franziska C.|last3=Pack|first3=Svetlana D.|last4=Mirvis|first4=Mariya|last5=Raffeld|first5=Mark|last6=Pittaluga|first6=Stefania|last7=Jaffe|first7=Elaine S.|date=2011-09-15|title=Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma|url=https://pubmed.ncbi.nlm.nih.gov/21768298|journal=Blood|volume=118|issue=11|pages=2976–2984|doi=10.1182/blood-2011-05-355255|issn=1528-0020|pmc=3175777|pmid=21768298}}</ref><ref>{{Cite journal|last=Sotomayor|first=Edgar A.|last2=Shah|first2=Inangati M.|last3=Sanger|first3=Warren G.|last4=Mark|first4=Hon Fong L.|date=2007-10-01|title=In situ follicular lymphoma with a 14;18 translocation diagnosed by a multimodal approach|url=https://www.sciencedirect.com/science/article/pii/S001448000700038X|journal=Experimental and Molecular Pathology|volume=83|issue=2|pages=254–258|doi=10.1016/j.yexmp.2007.03.001|issn=0014-4800}}</ref>
 |}
@@ Line 457: / Line 391: @@
 ==Additional Information==
-Put your text here
+This disease is <u>defined/characterized</u> as detailed below:
 ==Links==

Jennelleh at 13:32, 19 February 2025

2025-02-19T13:32:06Z

← Older revision		Revision as of 08:32, 19 February 2025
Line 77:		Line 77:
	Morphology is insufficient to diagnose ''in situ'' FL; immunhistochemistry and genetic testing for t(14;18) are necessary. GCs show monotonous morphology and lack tingible body macrophages. By IHC, cells show strong and uniform staining for BCL2 and CD10 and a low Ki67 index.<ref>{{Cite journal\|last=Vogelsberg\|first=Antonio\|last2=Steinhilber\|first2=Julia\|last3=Mankel\|first3=Barbara\|last4=Federmann\|first4=Birgit\|last5=Schmidt\|first5=Janine\|last6=Montes-Mojarro\|first6=Ivonne A.\|last7=Hüttl\|first7=Katrin\|last8=Rodriguez-Pinilla\|first8=Maria\|last9=Baskaran\|first9=Praveen\|date=2021\|title=Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype\|url=https://haematologica.org/article/view/9914\|journal=Haematologica\|language=en\|volume=106\|issue=10\|pages=2673–2681\|doi=10.3324/haematol.2020.254854\|issn=1592-8721\|pmc=PMC8485666\|pmid=32855278}}</ref>		Morphology is insufficient to diagnose ''in situ'' FL; immunhistochemistry and genetic testing for t(14;18) are necessary. GCs show monotonous morphology and lack tingible body macrophages. By IHC, cells show strong and uniform staining for BCL2 and CD10 and a low Ki67 index.<ref>{{Cite journal\|last=Vogelsberg\|first=Antonio\|last2=Steinhilber\|first2=Julia\|last3=Mankel\|first3=Barbara\|last4=Federmann\|first4=Birgit\|last5=Schmidt\|first5=Janine\|last6=Montes-Mojarro\|first6=Ivonne A.\|last7=Hüttl\|first7=Katrin\|last8=Rodriguez-Pinilla\|first8=Maria\|last9=Baskaran\|first9=Praveen\|date=2021\|title=Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype\|url=https://haematologica.org/article/view/9914\|journal=Haematologica\|language=en\|volume=106\|issue=10\|pages=2673–2681\|doi=10.3324/haematol.2020.254854\|issn=1592-8721\|pmc=PMC8485666\|pmid=32855278}}</ref>

	The following description of ISFN is derived from Jegalian et al<ref name=":1">{{Cite journal\|url=https://~~ashpublications~~.~~org/blood/article~~/118/11~~/2976/28482/Follicular-lymphoma-in-situ-clinical-implications~~\|doi=10.1182/blood-2011-05-355255\|pmc=~~PMC3175777~~\|pmid=21768298}}</ref>:		The following description of ISFN is derived from Jegalian et al<ref name=":1">{{Cite journal\|last=Jegalian\|first=Armin G.\|last2=Eberle\|first2=Franziska C.\|last3=Pack\|first3=Svetlana D.\|last4=Mirvis\|first4=Mariya\|last5=Raffeld\|first5=Mark\|last6=Pittaluga\|first6=Stefania\|last7=Jaffe\|first7=Elaine S.\|date=2011-09-15\|title=Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma\|url=https://pubmed.ncbi.nlm.nih.gov/21768298\|journal=Blood\|volume=118\|issue=11\|pages=2976–2984\|doi=10.1182/blood-2011-05-355255\|issn=1528-0020\|pmc=3175777\|pmid=21768298}}</ref>:

	*Unlike early-stage or partial involvement of FL, ''in situ'' FL retains follicular architecture with normal-sized follicles;		*Unlike early-stage or partial involvement of FL, ''in situ'' FL retains follicular architecture with normal-sized follicles;

Jennelleh at 13:28, 19 February 2025

2025-02-19T13:28:51Z

← Older revision		Revision as of 08:28, 19 February 2025
Line 407:		Line 407:
	\|		\|
	\|		\|
	\|Inactivating mutations prevent acetylation of the protein and creates an environment permissive for accumulation of mutations<ref>{{Cite journal\|last=Schmidt\|first=Janine\|last2=Ramis-Zaldivar\|first2=Joan Enric\|last3=Bonzheim\|first3=Irina\|last4=Steinhilber\|first4=Julia\|last5=Müller\|first5=Inga\|last6=Haake\|first6=Andrea\|last7=Yu\|first7=Shan Chi\|last8=Raffeld\|first8=Mark\|last9=Fend\|first9=Falko\|date=2018-12-20\|title=CREBBP gene mutations are frequently detected in in situ follicular neoplasia\|url=https://~~www~~.~~sciencedirect~~.~~com~~/~~science/article/pii/S0006497120429210~~\|journal=Blood\|volume=132\|issue=25\|pages=2687–2690\|doi=10.1182/blood-2018-03-837039\|issn=~~0006~~-~~4971~~}}</ref>. Mutations in ''CREBBP'' are thought to be early driver mutations and possibly necessary for transformation to FL, as they have been found in ISFN and paired FL samples<ref~~>{{Cite journal\|last=Schmidt\|first=Janine\|last2=Ramis-Zaldivar\|first2=Joan Enric\|last3=Bonzheim\|first3=Irina\|last4~~=Steinhilber\|first4=Julia\|last5=Müller\|first5=Inga\|last6=Haake\|first6=Andrea\|last7=Yu\|first7=Shan Chi\|last8=Raffeld\|first8=Mark\|last9=Fend\|first9=Falko\|date=2018-12-20\|title=CREBBP gene mutations are frequently detected in in situ follicular neoplasia\|url=https:/~~/www.sciencedirect.com/science/article/pii/S0006497120429210\|journal=Blood\|volume=132\|issue=25\|pages=2687–2690\|doi=10.1182/blood-2018-03-837039\|issn=0006-4971}}</ref~~>.		\|Inactivating mutations prevent acetylation of the protein and creates an environment permissive for accumulation of mutations<ref name=":2">{{Cite journal\|last=Schmidt\|first=Janine\|last2=Ramis-Zaldivar\|first2=Joan Enric\|last3=Bonzheim\|first3=Irina\|last4=Steinhilber\|first4=Julia\|last5=Müller\|first5=Inga\|last6=Haake\|first6=Andrea\|last7=Yu\|first7=Shan Chi\|last8=Raffeld\|first8=Mark\|last9=Fend\|first9=Falko\|date=2018-12-20\|title=CREBBP gene mutations are frequently detected in in situ follicular neoplasia\|url=https://pubmed.ncbi.nlm.nih.gov/30401710\|journal=Blood\|volume=132\|issue=25\|pages=2687–2690\|doi=10.1182/blood-2018-03-837039\|issn=1528-0020\|pmc=6302496\|pmid=30401710}}</ref>. Mutations in ''CREBBP'' are thought to be early driver mutations and possibly necessary for transformation to FL, as they have been found in ISFN and paired FL samples<ref name=":2" />.
	<br />		<br />
	\|-		\|-

Jennelleh at 13:26, 19 February 2025

2025-02-19T13:26:17Z

← Older revision		Revision as of 08:26, 19 February 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:In situ follicular B-cell neoplasm}}		{{DISPLAYTITLE:In situ follicular B-cell neoplasm}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

	{{Under Construction}}		{{Under Construction}}

	<blockquote class='blockedit'>{{Box-round\|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification\|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:In Situ Follicular Neoplasia]].		<blockquote class="blockedit">{{Box-round\|title=Content Update To WHO 5th Edition Classification Is In Process; Content Below is Based on WHO 4th Edition Classification\|This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:In Situ Follicular Neoplasia]].
	}}</blockquote>		}}</blockquote>

Line 76:		Line 77:
	Morphology is insufficient to diagnose ''in situ'' FL; immunhistochemistry and genetic testing for t(14;18) are necessary. GCs show monotonous morphology and lack tingible body macrophages. By IHC, cells show strong and uniform staining for BCL2 and CD10 and a low Ki67 index.<ref>{{Cite journal\|last=Vogelsberg\|first=Antonio\|last2=Steinhilber\|first2=Julia\|last3=Mankel\|first3=Barbara\|last4=Federmann\|first4=Birgit\|last5=Schmidt\|first5=Janine\|last6=Montes-Mojarro\|first6=Ivonne A.\|last7=Hüttl\|first7=Katrin\|last8=Rodriguez-Pinilla\|first8=Maria\|last9=Baskaran\|first9=Praveen\|date=2021\|title=Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype\|url=https://haematologica.org/article/view/9914\|journal=Haematologica\|language=en\|volume=106\|issue=10\|pages=2673–2681\|doi=10.3324/haematol.2020.254854\|issn=1592-8721\|pmc=PMC8485666\|pmid=32855278}}</ref>		Morphology is insufficient to diagnose ''in situ'' FL; immunhistochemistry and genetic testing for t(14;18) are necessary. GCs show monotonous morphology and lack tingible body macrophages. By IHC, cells show strong and uniform staining for BCL2 and CD10 and a low Ki67 index.<ref>{{Cite journal\|last=Vogelsberg\|first=Antonio\|last2=Steinhilber\|first2=Julia\|last3=Mankel\|first3=Barbara\|last4=Federmann\|first4=Birgit\|last5=Schmidt\|first5=Janine\|last6=Montes-Mojarro\|first6=Ivonne A.\|last7=Hüttl\|first7=Katrin\|last8=Rodriguez-Pinilla\|first8=Maria\|last9=Baskaran\|first9=Praveen\|date=2021\|title=Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype\|url=https://haematologica.org/article/view/9914\|journal=Haematologica\|language=en\|volume=106\|issue=10\|pages=2673–2681\|doi=10.3324/haematol.2020.254854\|issn=1592-8721\|pmc=PMC8485666\|pmid=32855278}}</ref>

	The following description of ISFN is derived from Jegalian et al<ref>{{Cite journal\|url=https://ashpublications.org/blood/article/118/11/2976/28482/Follicular-lymphoma-in-situ-clinical-implications\|doi=10.1182/blood-2011-05-355255\|pmc=PMC3175777\|pmid=21768298}}</ref>:		The following description of ISFN is derived from Jegalian et al<ref name=":1">{{Cite journal\|url=https://ashpublications.org/blood/article/118/11/2976/28482/Follicular-lymphoma-in-situ-clinical-implications\|doi=10.1182/blood-2011-05-355255\|pmc=PMC3175777\|pmid=21768298}}</ref>:

	*Unlike early-stage or partial involvement of FL, ''in situ'' FL retains follicular architecture with normal-sized follicles;		*Unlike early-stage or partial involvement of FL, ''in situ'' FL retains follicular architecture with normal-sized follicles;
Line 203:		Line 204:
	\|No		\|No
	\|No		\|No
	\|The translocation results in the juxtaposition of the BCL2 major or minor breakpoint cluster with the VDJ region of IGH during erroneous VDJ recombination<ref~~>{{Cite journal\|url~~=~~https~~:/~~/ashpublications.org/blood/article/118/11/2976/28482/Follicular-lymphoma-in-situ-clinical-implications\|doi=10.1182/blood-2011-05-355255\|pmc=PMC3175777\|pmid=21768298}}</ref~~><ref>{{Cite journal\|last=Sotomayor\|first=Edgar A.\|last2=Shah\|first2=Inangati M.\|last3=Sanger\|first3=Warren G.\|last4=Mark\|first4=Hon Fong L.\|date=2007-10-01\|title=In situ follicular lymphoma with a 14;18 translocation diagnosed by a multimodal approach\|url=https://www.sciencedirect.com/science/article/pii/S001448000700038X\|journal=Experimental and Molecular Pathology\|volume=83\|issue=2\|pages=254–258\|doi=10.1016/j.yexmp.2007.03.001\|issn=0014-4800}}</ref>		\|The translocation results in the juxtaposition of the BCL2 major or minor breakpoint cluster with the VDJ region of IGH during erroneous VDJ recombination<ref name=":1" /><ref>{{Cite journal\|last=Sotomayor\|first=Edgar A.\|last2=Shah\|first2=Inangati M.\|last3=Sanger\|first3=Warren G.\|last4=Mark\|first4=Hon Fong L.\|date=2007-10-01\|title=In situ follicular lymphoma with a 14;18 translocation diagnosed by a multimodal approach\|url=https://www.sciencedirect.com/science/article/pii/S001448000700038X\|journal=Experimental and Molecular Pathology\|volume=83\|issue=2\|pages=254–258\|doi=10.1016/j.yexmp.2007.03.001\|issn=0014-4800}}</ref>
	\|}		\|}

Line 472:		Line 473:

	<nowiki>*</nowiki>''Citation of this Page'': “In situ follicular B-cell neoplasm”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:In_situ_follicular_B-cell_neoplasm</nowiki>.		<nowiki>*</nowiki>''Citation of this Page'': “In situ follicular B-cell neoplasm”. Compendium of Cancer Genome Aberrations (CCGA), Cancer Genomics Consortium (CGC), updated {{REVISIONMONTH}}/{{REVISIONDAY}}/{{REVISIONYEAR}}, <nowiki>https://ccga.io/index.php/HAEM5:In_situ_follicular_B-cell_neoplasm</nowiki>.
	[[Category:HAEM5]][[Category:DISEASE]][[Category:Diseases I]]		[[Category:HAEM5]]
			[[Category:DISEASE]]
			[[Category:Diseases I]]

Bailey.Glen: /* Gene Mutations (SNV/INDEL) */

2025-02-13T22:33:06Z

Gene Mutations (SNV/INDEL)

@@ Line 343: / Line 343: @@
 |}
 ==Gene Mutations (SNV/INDEL)==
 Put your text here and fill in the table

Bailey.Glen: /* Individual Region Genomic Gain/Loss/LOH */

2025-02-13T22:32:34Z

Individual Region Genomic Gain/Loss/LOH

@@ Line 207: / Line 207: @@
 ==Individual Region Genomic Gain/Loss/LOH==
 Put your text here and fill in the table
@@ Line 252: / Line 304: @@
 Common recurrent secondary finding for t(8;21) (add reference).
 |}
 ==Characteristic Chromosomal or Other Global Mutational Patterns==